Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer

Infectious Agents and Cancer

Aizada Chinybayeva¹  Arnat Balabiyev¹  Damel Mektepbayeva¹  Madina Shaimerdenova³  Nurgul Imangali³  Yeldar Baiken¹  Aliya Bekmurzayeva¹  Ainur Kakpenova¹  Zarina Sautbayeva¹  Stephanie Irving¹  Kenneth Alibek² 

[1] Nazarbayev University Research and Innovation System (NURIS), Nazarbayev University, 53 Kabanbay Batyr Avenue, Astana 010000, Kazakhstan;National Medical Holding, 2 Syganak Street, Astana 010000, Kazakhstan;School of Science and Technology, Nazarbayev University, 53 Kabanbay Batyr Avenue, Astana 010000, Kazakhstan

关键词: Cancer;    Tumor suppressor genes;    Signaling pathways;    Apoptosis;    Hepatitis C virus;    Human papillomavirus;    Human T-lymphotropic virus 1;    Herpesviruses;    Bcl-xL;    Bcl-2;   

Others  :  1133750
DOI  :  10.1186/1750-9378-9-44

 received in 2014-09-23, accepted in 2014-11-25,  发布年份 2014

【 摘 要 】

The Bcl proteins play a critical role in apoptosis, as mutations in family members interfere with normal programmed cell death. Such events can cause cell transformation, potentially leading to cancer. Recent discoveries indicate that some viral proteins interfere with Bcl proteins either directly or indirectly; however, these data have not been systematically described. Some viruses encode proteins that reprogramme host cellular signalling pathways controlling cell differentiation, proliferation, genomic integrity, cell death, and immune system recognition. This review analyses and summarises the existing data and discusses how viral proteins interfere with normal pro- and anti-apoptotic functions of Bcl-2 and Bcl-xL. Particularly, this article focuses on how viral proteins, such as Herpesviruses, HTLV-1, HPV and HCV, block apoptosis and how accumulation of such interference predisposes cancer development. Finally, we discuss possible ways to prevent and treat cancers using a combination of traditional therapies and antiviral preparations that are effective against these viruses.

【 授权许可】

   
2014 Alibek et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]McLaughlin-Druber ME, Munger L: Viruses associated with human cancer. Biochem Biophisica Acta 2008, 1782:127-150.
• [2]Kirkin V, Joos S, Zornig M: The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta-Mol Cell Res 2004, 1644:229-249.
• [3]Reed JC: Bcl-2 family proteins. Oncogene 1998, 17:3225-3236.
• [4]Gross A: BCL-2 proteins: regulators of the mitochondrial apoptotic program. IUBMB Life 2001, 52:231-236.
• [5]Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: BCL-2 Is an inner mitochondrial-membrane protein that blocks programmed cell-death. Nature 1990, 348:334-336.
• [6]Hsu YT, Youle RJ: Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 1997, 272:13829-13834.
• [7]Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
• [8]Cory S, Adams JM: The BCL2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
• [9]Kvansakul M, Hinds MG: Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis 2013, 4:1-10.
• [10]Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ: Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 2001, 153:1265-1276.
• [11]Dewson G, Kluck R: Bcl-2 family-regulated apoptosis in health and disease. Cell Health Cytoskeleton 2010, 2:9-22.
• [12]Newmeyer DD, Farschon DM, Reed JC: Cell-free apoptosis in xenopus egg extracts inhibition by bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994, 79:53-64.
• [13]Flanagan AM, Letai A: BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death Differ 2008, 15:580-588.
• [14]Inhibition of Apoptosis Signaling Pathway: Inhibition of Apoptosis Signaling Pathway. http://www.cellsignal.com/contents/science-pathway-research-apoptosis/inhibition-ofapoptosis-signaling-pathway/pathways-apoptosis-inhibition webcite
• [15]Fu Q, He C, Mao ZR: Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells. J Zhejiang Univ-Sci B 2013, 14:8-24.
• [16]Hardwick JM, Bellows DS: Viral versus cellular BCL-2 proteins. Cell Death Differ 2003, 10:S68-S76.
• [17]Lu JJY, Chen JY, Hsu TY, Yu WCY, Su IJ, Yang CS: Cooperative interaction between Bcl-2 and Epstein-Barr virus latent membrane protein 1 in the growth transformation of human epithelial cells. J Gen Virol 1997, 78:2975-2985.
• [18]Murray P, Swinnen L, Constandinou C, Pyle J, Carr T, Hardwick M, Ambinder RF: BCL-2 but not its Epstein-Barr Virus-encoded homologue, BHRF1, is commonly expressed in Posttransplantation Lymphoproliferative Disorders. Blood 1996, 87:706-711.
• [19]Kvansakul M, Wei AH, Fletcher K, Willis SN, Chen L: Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathog 2010, 6:1-10.
• [20]Bellows DS, Howell M, Pearson C, Hazlewood SA, Hardwick JM: Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins. J Virol 2002, 76:2469-2479.
• [21]Marshall WL, Yim C, Gustafson E, Graf T, Sage DR, Hanify K, Williams L, Fingeroth J, Finberg RW: Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J Virol 1999, 73:5181-5185.
• [22]Alibek K, Baiken Y, Kakpenova A, Mussabekova A, Zhussupbekova S, Akan M, Sultankulov B: Implication of human herpesviruses in oncogenesis through immune evasion and suppression. Infect Agents Canc 2014, 9:1-8. BioMed Central Full Text
• [23]Sinclair J, Sissons P: Latency and reactivation of human cytomegalovirus. J Gen Virol 2006, 87:1763-1779.
• [24]Andoniou CE, Degli-Esposti MA: Insights into the mechanisms of CMV-mediated interference with cellular apoptosis. Immunol Cell Biol 2006, 84:99-106.
• [25]Zhang A, Hildreth RL, Colberg-Poley AM: Human cytomegalovirus inhibits apoptosis by proteasome-mediated degradation of bax at endoplasmic reticulum-mitochondrion contacts. J Virol 2013, 87:5657-5668.
• [26]McCormick AL: Control of apoptosis by human cytomegalovirus. Hum Cytomegalovirus 2008, 325:281-295.
• [27]Fedorova NE, Sokolova TM, Medzhidova MG, Kushch AA: Different regulation of mitochondrial apoptosis and Bcl-2 gene expression in quescent and proliferative human fibroblasts infected with cytomegalovirus. Tsitologiia 2010, 52:168-176.
• [28]Lares AP, Tu CC, Spencer JV: The human cytomegalovirus US27 gene product enhances cell proliferation and alters cellular gene expression. Virus Res 2013, 176:12-20.
• [29]Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE: Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007, 9:470-478.
• [30]Khan KA, Coaquette A, Davrinche C, Herbein G: Bcl-3-regulated transcription from major immediate-early promoter of human cytomegalovirus in monocyte-derived macrophages. J Immunol 2009, 182:7784-7794.
• [31]Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 16:1865-1869.
• [32]Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995, 4:1186-1191.
• [33]Corbellino M, Poirel L, Aubin JT, Paulli M, Magrini U, Bestetti G, Galli M, Parravicini C: The role of human herpesvirus 8 and Epstein-Barr virus in the pathogenesis of giant lymph node hyperplasia (Castleman’s disease). Clin Infect Dis 1996, 22:1120-1121.
• [34]Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS: Nucleotide sequence of the Kaposi sarcoma associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996, 93:14862-14867.
• [35]Moore PS, Chang Y: Molecular virology of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 2001, 356:499-516.
• [36]West JT, Wood C: The role of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene 2003, 22:5150-5163.
• [37]Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS: Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003, 3:23-36.
• [38]Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET: Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc Natl Acad Sci USA 2002, 99:3428-3433.
• [39]Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW: Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275:983-986.
• [40]Suzuki M, Youle RJ, Tjandra N: Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000, 103:645-654.
• [41]Loh J, Huang Q, Petros AM, Nettesheim D, van Dyk LF, Labrada L, Speck SH, Levine B, Olejniczak ET, Virgin HW 4th: A surface groove essential for viral Bcl-2 function during chronic infection in vivo. PLoS Pathog 2005, 1:e10.
• [42]Wei Y, Pattingre S, Sinha S, Bassik M, Levine B: JNK1-mediated phosphorylation of Bcl 2 regulates starvation-induced autophagy. Mol Cell 2008, 30:678-688.
• [43]Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM: Molecular genetics of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 2003, 67:175-212.
• [44]Cuconati A, White E: Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev 2002, 16:2465-2478.
• [45]Cheng EH-Y, Nicholas J, Bellows DS, Hayward GS, Guo H-G, Reitz MS, Hardwick JM: A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 1997, 94:690-694.
• [46]Sarid R, Sata T, Bohenzky RA, Russo JJ, Chang Y: Kaposi’s sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997, 3:293-298.
• [47]Widmer I, Wernli M, Bachmann F, Gudat F, Cathomas G, Erb P: Differential expression of viral Bcl 2 encoded by Kaposi’s sarcoma-associated herpesvirus and human Bcl-2 in primary effusion lymphoma cells and Kaposi’s sarcoma lesions. J Virol 2002, 76:2551-2556.
• [48]Ojala PM, Yamamoto K, Castanos-Velez E, Biberfeld P, Korsmeyer SJ, Makela TP: The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol 2000, 2:819-825.
• [49]Bellows DS, Chau BN, Lee P, Lazebnik Y, Burns WH, Hardwick JM: Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins. J Virol 2000, 74:5024-5031.
• [50]Walensky LD: BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006, 13:1339-1350.
• [51]Kalt I, Borodianskiy-Shteinberg T, Schachor A, Sarid R: GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi’s Sarcoma Associated Herpesvirus KS-Bcl-2 protein. J Virol 2010, 84:2935-2945.
• [52]Bernard HU: The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005, 32S:S1-S6.
• [53]Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
• [54]Harwood CA, Surentheran T, Sasieni P, Proby CM, Bordea C, Leigh IM, Wojnarowska F, Breuer J, McGregor JM: Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004, 150:949-957.
• [55]Doorbar J, Foo C, Coleman N, Medcalf E, Hartley O, Prospero T, Napthine S, Sterling J, Winter G, Griffin H: Characterisation of events during the late stages of HPV16 infection in vivo using high affinity synthetic fabs to E4. Virology 1997, 238:40-52.
• [56]Culp TD, Christensen N: Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology 2004, 319:152-161.
• [57]Wilson VG, West M, Woytek K, Rangasamy D: Papillomavirus E1 proteins: form, function, and features. Virus Genes 2002, 24:275-290.
• [58]Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-9788.
• [59]Lee JO, Russo AA, Pavletich NP: Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998, 391:859-865.
• [60]Longworth MS, Laimins LA: The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 2004, 78:3533-4351.
• [61]Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA: Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV16 E7 oncoprotein. Genes Dev 1997, 11:2090-2100.
• [62]Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
• [63]Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, Herman B: Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995, 57:509-521.
• [64]Nguyen MM, Nguyen ML, Caruana G, Bernstein A, Lambert PF, Griep AE: Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol 2003, 23:8970-8981.
• [65]Middleton K, Peh W, Southern SA, Griffin HM, Sotlar K, Nakahara T, El-Sherif A: Organisation of the human papillomavirus productive cycle during neoplastic progression provides a basis for the selection of diagnostic markers. J Virol 2003, 77:10186-10201.
• [66]Leechanachai P, Banks L, Moreau F, Matlashewski G: The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992, 7:19-25.
• [67]Straight SW, Hinkle PM, Jewers RJ, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993, 67:4521-4532.
• [68]Williams SMG, Disbrow GL, Schlegel R, Lee D, Threadgill DW, Lambert PF: Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res 2005, 65:6534-6542.
• [69]Maufort JP, Williams SMG, Pitot HC, Lambert PF: Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res 2007, 67:6106-6112.
• [70]Valle GF, Banks L: The human papillomavirus (HPV)-6 and HPV-16 E5 proteins cooperate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol 1995, 76:1239-1245.
• [71]Oh JM, Kim SH, Cho EA, Song YS, Kim WH, Juhnn YS: Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by stimulating ubiquitin proteasome mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 2010, 31:402-410.
• [72]Mesri EA, Feitelson MA, Munger K: Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014, 15:266-282.
• [73]Wongstaal F, Gallo RC: Human t-lymphotropic retroviruses. Nature 1985, 317:395-403.
• [74]Simonis N, Rual J-F, Lemmens I, Boxus M, Hirozane-Kishikawa T, Gatot J-S, Dricot A, Hao T, Vertommen D, Legros S, Daakour S, Klitgord N, Martin M, Willaert J-F, Dequiedt F, Navratil V, Cusick ME, Burny A, Van Lint C, Hill DE, Tevernier J, Kettmann R, Vidal M, Twizere J-C: Host pathogen interactome mapping for HTLV-1 and −2 retroviruses. Retrovirology 2012, 9:2-20. BioMed Central Full Text
• [75]Chlichlia K, Khazaie K: HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death. Chem Biol Interact 2010, 188:59-65.
• [76]Harakeh S, Diab-Assaf M, Khalife JC, Abu-El-Ardat KA, Baydoun E, Niedzwiecki A, El-Sabban ME, Rath M: Ascorbic acid induces apoptosis in adult T-cell leukemia. Anticancer Res 2007, 27:289-298.
• [77]Azran I, Schavinsky-Khrapunsky Y, Aboud M: Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 2004, 1:1-24. BioMed Central Full Text
• [78]Taylor JM, Nicot C: HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches. Apoptosis 2008, 13:733-747.
• [79]Gatza ML, Watt JC, Marriott SJ: Cellular transformation by the HTLV-I Tax protein, a jack-of-all-trades. Oncogene 2003, 22:5141-5149.
• [80]Bogenberger JM, Laybourn PJ: Human T lymphotropic virus type 1 protein tax reduces histone levels. Retrovirology 2008, 5:9. BioMed Central Full Text
• [81]D’Agostino DM, Bernardi P, Chieco-Bianchi L, Ciminale V: Mitochondria as functional targets of proteins coded by human tumor viruses. Adv Cancer Res 2005, 94:87-142.
• [82]Grassmann R, Aboud M, Jeang KT: Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005, 24:5976-5985.
• [83]Ishikawa C, Nakachi S, Senba M, Sugai M, Mori N: Activation of AID by human T-cell leukemia virus Tax oncoprotein and the possible role of its constitutive expression in ATL genesis. Carcinogenesis 2011, 32:110-119.
• [84]Matsuoka MM, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280.
• [85]Macaire H, Riquet A, Moncollin V, Biemont-Trescol MC, Dodon MD, Hermine O, Debaud AL, Mahieux R, Mesnard JM, Pierre M, Gazzolo L, Bonnefoy N, Valentin H: Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells. J Biol Chem 2012, 287:34495-34495.
• [86]Nakashima K, Kawakami A, Hida A, Yamasaki S, Nakamura H, Kamachi M, Miyashita T, Tanaka F, Izumi Y, Tamai M, Ida H, Furuyama M, Koji T, Nakamura T, Migita K, Origuchi T, Eguchi K: Protection of mitochondrial perturbation by human T-lymphotropic virus type 1 tax through induction of Bcl-xL expression. J Lab Clin Med 2003, 142:341-347.
• [87]Qu Z, Xiao G: Human T-Cell lymphotropic virus: a model of NF-kappa B-associated tumorigenesis. Viruses-Basel 2011, 3:714-749.
• [88]Nicot C, Mahieux R, Takemoto S, Franchini G: Bcl-X-L is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000, 96:275-281.
• [89]Cook LB, Elemans M, Rowan AG, Asquith B: HTLV-1: persistence and pathogenesis. Virology 2013, 435:131-140.
• [90]Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, Yotsumoto F, Tanji H, Mori N, Takeshita M, Miyamoto S, Tamura K: Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett 2012, 317:218-225.
• [91]Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C, Baumann S, Holtkotte D, Bosch V, Krammer PH, Li-Weber M: HTLV-1 tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006, 107:3933-3939.
• [92]Brauweiler A, Garrus JE, Reed JC, Nyborg JK: Repression of Bax gene expression by the HTLV-I tax protein: implications for suppression of apoptosis in virally infected cells. Virology 1997, 231:135-140.
• [93]Reed JC, Zha HB, AimeSempe C, Takayama S, Wang HG: Structure-function analysis of bcl-2 family proteins - Regulators of programmed cell death. Mechanisms of Lymphocyte Activation and Immune Regulation. New York: Plenum Publ Corp; 1996:99-112.
• [94]Nair A, Michael B, Hiraragi H, Fernandez S, Feuer G, Boris-Lawrie K, Lairmore M: Human T lymphotropic virus type 1 accessory protein p12(I) modulates calcium-mediated cellular gene expression and enhances p300 expression in T lymphocytes. Aids Res Hum Retrovir 2005, 21:273-284.
• [95]Li Y, Zhang Q, Liu Y, Luo Z, Kang L, Qu J, Liu W, Xia X, Liu Y, Wu K, Wu J: Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signalling pathways. J Virol 2012, 86:12531-12543.
• [96]Alenzi FQ, El-Nashar EM, Al-Ghamdi SS, Abbas MY, Hamad AM, El-Saeed OM, Wyse RKH, Lofty M: Investigation of Bcl-2 and PCNA in hepatocellular carcinoma: relation to chronic HCV. J Egypt Natl Canc Inst 2010, 22:87-92.
• [97]Fabregat I: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 7:513-552.
• [98]Zekri ARN, Bahnassy AA, Hafez MM, Hassan ZK, Kamel M, Loufty SA, Sherif GM, El Zayadi AR, Daoud SS: Characterization of chronic HCV infection-induced apoptosis. Comp Hepatol 2011, 10:1-14. BioMed Central Full Text
• [99]Houghton M, Weiner A, Han J, Kuo G, Choo QL: Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991, 14:381-388.
• [100]Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A: Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002, 196:641-653.
• [101]Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y, Omata M: Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. Virology 2002, 296:84-93.
• [102]Chou AH, Tsai HF, Wu YY, Hu CY, Hwang LH, Hsu PI, Hsu PN: Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 2005, 174:2160-2166.
• [103]Gao L, Aizaki H, He JW, Lai MM: Interactions between viral non-structural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 2004, 78:3480-3488.
• [104]Gong G, Waris G, Tanveer R, Siddiqui A: Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001, 98:9599-9604.
• [105]Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y, Padmanabhan R: Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 2001, 276:12675-12684.
• [106]Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, Wang YJ, Kato N, Omata M, Chang FY, Lee SD: HCV NS5A interacts with p53 and inhibits p53-mediated Apoptosis. Oncogene 2002, 21:4801-4811.
• [107]Korsmeyer SJ: Regulators of cell death. Trends Genet 1995, 11:101-105.
• [108]Wang J, Tong W, Zhang X, Chen L, Yi Z, Pan T, Hu Y, Xiang L, Yuan Z: Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Lett 2006, 580:4392-4400.
• [109]Chung YL, Sheu ML, Yen SH: Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer 2003, 107:65-73.
• [110]Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW: Enforced bcl2 expression in b-lymphoid cells prolongs antibody-responses and elicits autoimmune-disease. Proc Natl Acad Sci U S A 1991, 88:8661-8665.
• [111]Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ: Bcl-2 inhibits multiple forms of apoptosis but not negative selection in THYMOCYTES. Cell 1991, 67:879-888.
• [112]Schmitt CA, Rosenthal CT, Lowe SW: Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000, 6:1029-1035.
• [113]Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000, 60:6101-6110.
• [114]Middleton T, Gahn TA, Martin JM, Sugden B: Immortalizing genes of Epstein-Barr-virus. Adv Virus Res 1991, 40:19-55.
• [115]Henderson S, Rowe M, Gregory C, Croomcarter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr-virus latent membrane protein-1 protects infected B-cells from programmed cell-death. Cell 1991, 65:107-115.
• [116]Kenney JL, Guinness ME, Curiel F, Lacy J: Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and Bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92:1721-1727.
• [117]Guinness ME, Kenney JL, Reiss M, Lacy J: Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res 2000, 60:5354-5358.
• [118]Johnsen JI, Baryawno N, Soderberg-Naucler C: Is human cytomegalovirus a target in cancer therapy? Oncotarget 2011, 2:1329-1338.
• [119]Biron KK: Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006, 71:154-163.
• [120]Schreiber A, Haerter G, Schubert A, Bunjes D, Mertens T, Michel D: Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin Pharmacother 2009, 10:191-209.
• [121]Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong L-Y, Wu A, Wang Y, Cahill D, Levine N, Prabhu S, Rao G, Sawaya R, Heimberger AB: Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res 2011, 17:4642-4649.
• [122]Sampson JH, Mitchell DA: Is cytomegalovirus a therapeutic target in glioblastoma? Clin Cancer Res 2011, 17:4619-4621.
• [123]Wen KW, Damania B: Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010, 289:140-150.
• [124]Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM: Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Investig 2007, 117:1019-1028.
• [125]Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C: Inhibiting primary effusion lymphoma, by lentiviral vectors encoding short hairpin RNA. Blood 2005, 105:2510-2518.
• [126]Stallone G, Schena A, Infante B, DiPaolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for kaposi’s sarcoma in renal – transplant recipients. N Engl J Med 2005, 352:1317-1323.
• [127]Jiang M, Milner J: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002, 21:6041-6048.
• [128]Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Haupt RM, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al.: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Canc Prev Res 2009, 2(10):1940-6207.
• [129]Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
• [130]Pang CL, Thierry F: Human papillomavirus proteins as prospective therapeutic targets. Microb Pathog 2013, 58:55-65.
• [131]Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Chen SL: Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 2000, 74:9083-9089.
• [132]Kfoury Y, Nasr R, Hermine O, de The H, Bazarbachi A: Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kB pathway. Cell Death Differ 2005, 12:871-877.
• [133]Nasr R, El Hajj H, Kfoury Y, de Thé H, Hermine O, Bazarbachi A: Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects? Viruses 2011, 3:751-769.
• [134]Dewan MZ, Uchihara J, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N: Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006, 107:716-724.
• [135]Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H: Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005, 4:578-586.
• [136]Zhang J, Nagasaki M, Tanaka Y, Morikawa S: Capsaicin inhibits growth of adult T-cell leukemia cells. Leuk Res 2003, 27:275-283.
• [137]Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PA, Bazarbachi A: EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood 2008, 111:3770-3777.
• [138]Fischer R, Baumert T, Blum HE: Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007, 13:4865-4872.
• [139]Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
• [140]Lawitz EJ, Rodriguez-Torres M, Muir A, Keane J, Kieffer T, McNair L, McHutchinson JG: 28 Days of the hepatitis C protease inhibitor VX-950, in combination with PEG Interferon-α-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 2006, 131:950-951.
• [141]Cholongitas E, Papatheodoridis GV: Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 2014, 27(4):331-337.
• [142]Pawlotsky JM, McHutchison JG: Hepatitis C: Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 2004, 39:554-567.
• [143]Soriano V, Peters MG, Zeuzem S: New therapies for hepatitis C virus infection. Clin Infect Dis 2009, 48:313-320.